Jasper Therapeutics, Inc.
JSPR
$4.87
$0.020.41%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 18.24% | 41.72% | 20.38% | 3.69% | 15.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.65% | 42.65% | 2.72% | -10.29% | 8.07% |
| Operating Income | -44.65% | -42.65% | -2.72% | 10.29% | -8.07% |
| Income Before Tax | -54.73% | -46.68% | -6.23% | 9.31% | 3.73% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -54.73% | -46.68% | -6.23% | 9.31% | 3.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.73% | -46.68% | -6.23% | 9.31% | 3.73% |
| EBIT | -44.65% | -42.65% | -2.72% | 10.29% | -8.07% |
| EBITDA | -45.58% | -43.56% | -1.37% | 10.59% | -8.13% |
| EPS Basic | -37.35% | -7.94% | 22.30% | 33.91% | 36.56% |
| Normalized Basic EPS | -37.35% | -7.76% | 23.67% | 35.59% | 32.97% |
| EPS Diluted | -37.35% | -7.94% | 22.30% | 33.91% | 36.56% |
| Normalized Diluted EPS | -37.35% | -7.76% | 23.67% | 35.59% | 32.97% |
| Average Basic Shares Outstanding | 12.65% | 35.89% | 36.72% | 37.22% | 51.74% |
| Average Diluted Shares Outstanding | 12.65% | 35.89% | 36.72% | 37.22% | 51.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |